Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Number of holders
-
49
-
Total 13F principal, excl. options
-
392M
-
Principal change
-
+13.3M
-
Total reported value, excl. options
-
$305M
-
Value change
-
-$475K
-
Number of buys
-
26
-
Number of sells
-
-17
-
Price
-
$0.78
Significant Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q3 2017
53 filings reported holding 45845PAA6 - INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q3 2017.
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 has 49 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $392M of principal
.
Largest 10 bondholders include HIGHFIELDS CAPITAL MANAGEMENT LP ($72.3M of principal), DEERFIELD MANAGEMENT CO ($51M of principal), Allianz Asset Management GmbH ($46.4M of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($24.8M of principal), AMERIPRISE FINANCIAL INC ($20.3M of principal), MACKAY SHIELDS LLC ($18M of principal), CITADEL ADVISORS LLC ($17.8M of principal), JPMORGAN CHASE & CO ($13.2M of principal), STATE STREET CORP ($12.2M of principal), and Polar Capital LLP ($11.5M of principal).
This table shows the top 49 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.